Sciclone Pharma (SCLN) Reports Q2 EPS of $0.20

Sciclone Pharma (NASDAQ: SCLN) reported Q2 EPS of $0.20, versus $0.26 reported last year. Revenue for the quarter came in at $39 million, versus $37.9 million reported last year.

Outlook for 2016

SciClone projects its 2016 revenue to be in the range of $158 million to $163 million and expects that non-GAAP earnings per share on a fully diluted basis to be in the range of $0.70 to $0.74 for the year.

For earnings history and earnings-related data on Sciclone Pharma (SCLN) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c
• Femasys Inc. (FEMY) Misses Q2 EPS by 20c